Published: 2018-03-28

Derangement in lipid profile in nephrotic syndrome in children

Arnab Biswas, Rajarshi Basu


Background: Hyperlipidemia, an important characteristic of idiopathic nephrotic syndrome in children (NS),

thereby makes them prone to develop premature atherosclerosis and related complications.

Methods: We have investigated the changes in different fractions of lipids and apolipoproteins level in thirty

children of 1-12 years of age with idiopathic nephrotic syndrome. Twenty-six age and sex matched hospitalized

children, suffering from non-renal diseases, were enrolled as controls.

Results: The results revealed that ApoB along with cholesterol, triglyceride and LDL-cholesterol, were significantly increased (p<0.001), whereas apoA1 and HDL-cholesterol were unaltered in the patients compared to the controls. Further, the ratios cholesterol: HDL-cholesterol, triglyceride: HDL-cholesterol and LDL cholesterol: HDL-cholesterol were also increased (p<0.001) and apoA1: apoB were lowered (p<0.001) in patients of nephrotic syndrome.

Conclusions: Therefore, there is a need to evaluate the lipid and lipoprotein levels early and so that appropriate therapy can be offered to selective candidates.


Apolipoprotein, Cholesterol, Hyperlipidemia, Nephrotic syndrome, Triglyceride

Full Text:



Togawa A, Yamamoto T, Hishida A. Nephrotic syndrome: pathophysiology, classification and diagnostic criteria. Nippon Rinsho. 2004;62(10):1777-83.

Kari JA, Tashkandi M, Medhat AM, Khoja SO, Ramadan KS. Lipoprotein (a) and other dyslipidemia in Saudi children with nephrotic syndrome (SSNS and SRNS). J Health Sci. 2012;2(6):57-63.

McGowan M, Artiss J, Strandbergh DR. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem. 1983;29:538.

Allain CC, Poon LS, Chan CS. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470.

Warnick GR, Nauck M, Rifai N. Evolution of methods of measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem. 2001;47:1579-96.

Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem. 2002;48:236.

Bhatnagar D, Durrington PM. Measurement and clinical significance of apoproteons A1 and B. In: Rifai N, Warnick GR, Dominczak MH, eds. Handbook of lipoprotein testing, 2nd Ed. Washington D.C.: AACC Press;2000:287.

Nosratola DV, Kaihuli L. Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol regulatory enzymes and receptors in nephrotic syndrome. American J Nephrol. 2004;24:606-13.

Mérouani A1, Lévy E, Mongeau JG, Robitaille P, Lambert M, Delvin EE. Hyperlipidemic profiles during remission in childhood idiopathic nephrotic syndrome. Clin Biochem. 2003;36(7):571-4.

Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences and treatment. Am J Kidney Dis. 1994;23:331-46.

De Sain-Vander Velden VMG, Kaysen GA, Barrett HA, Stellaard F, Gaoellaa MM, Voorbij HA, et al. Increased VLDL in nephritic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Inter. 1998;53(4):994-1101.

Marsh JB, Sparks CE. Hepatic secretion of lipoproteins in the rat and the effect of experimental nephrosis. J Clin Invest 1979;64:1229-37.

Mahmud S1, Jahan S, Hossain MM. Hyperlipidemia in childhood idiopathic nephrotic syndrome during initial remission and relapse. Mymensingh Med J. 2011;20(3):402-6.

Kaysen GA, Gambertoglio J, Felts J, Hutchinson FN. Albumin synthesis, albuminuria and hyperlipemia in nephritic patients. Kidney Inter. 1987;31:1368-76.

Marenah CB. Lipid metabolism, hyper- and hypo-lipidemias and atherosclerosis. In: Marshall WJ, Bangert SK, eds. Clinical Biochemistry: metabolic and clinical aspects. 1st Ed. New York: Churchill Livingstone;1995:621-40.

Kaysen GA. Proteinuria and the nephritic syndrome. In: Schrier RW, ed. Renal and electrolyte disorders. 5th Ed. New York: Lippincott Raven;1997:640-84.

Marsh JB. Lipoprotein metabolism in the nephrotic syndrome. Front Biosci. 2002;1(7): e326-e338.

Joles JA, Bijlveld C, Van Tol A, Geelen MJH, Koomans HA. Plasma triglyceride levels are higher in nephritic than in analbuminemic rats despite a similar increase in hepatic triglyceride secretion. Kidney Inter. 1995;47(2):701-08.

Liang K, Vaziri ND. Acquired VLDL receptor deficiency in experimental nephrosis. Kidney Inter. 1997;51:1761-65.

Kronenberg F. Dyslipidemia and nephrotic syndrome: recent advances. J Ren Nutr. 2005;15(2):195-203.

Hopp L, Gilboa N, Kurland G, Weichler N, Orchard TJ. Acute myocardial infarction in a young boy with nephrotic syndrome: a case report and review of literature. Pediatr Nephrol. 1994;8:290-94.

Kniazewska MH, Obuchowicz AK, Wielkoszynski T, Zmudzinska-Kitczak J, Urban K, Marek M, et al. Atherosclerosis risk factors in young patients formerly treated for idiopathic nephrotic syndrome. Pediatr Nephrol. 2009;24(3):549-54.

Keane WF, Kasiske BL, O’Donnell P, Kim Y. The role of altered lipid metabolism in the progression of renal disease:experimental evidence. Am Jr Kid Dis. 1991;17:38-42.